3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
107
Genitourinary
5
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Endocrine
1
Classical hematology
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Lung Neoplasms
12
Small Cell Lung Carcinoma
4
Carcinoma, Renal Cell
4
Triple Negative Breast Neoplasms
2
Neuroendocrine Tumors
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Mesothelioma
2
Thymoma
1
Somatostatinoma
1
Recurrence
1
Pheochromocytoma
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Insulinoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Glucagonoma
1
Gastrointestinal Neoplasms
1
Gastrinoma
1
Colorectal Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoma, Medullary
1
Carcinoma, Large Cell
1
Carcinoma, Islet Cell
1
Breast Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
38
Docetaxel
23
Paclitaxel
20
Trastuzumab
19
Cyclophosphamide
18
Gemcitabine
17
Carboplatin
17
Magnetic Resonance Spectroscopy
16
Radiotherapy
14
Nivolumab
13
Radiosurgery
12
Surveys and Questionnaires
11
Specimen Handling
10
Fulvestrant
10
fludarabine
9
aldesleukin
9
Vinorelbine
9
Blood Specimen Collection
9
Taxes
8
Injections
8
Drug Therapy
8
Cisplatin
8
Capecitabine
8
Bevacizumab
8
Standard of Care
7
Psychiatric Rehabilitation
7
Fluorodeoxyglucose F18
7
Early Intervention, Educational
7
sargramostim
6
palbociclib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Everolimus
×
Thoracic
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled